Dr Reddy’s Dishes On Denosumab, Abatacept Filings Amid ‘Steady’ Q1
Biosimilar Investment ‘Very, Very Important’; Growing Capacity In Bachupally
Dr Reddy’s has provided key expected dates for movement on its slate of pending biosimilars, as it continues to drive towards a meaningful impact from biosimilars in key markets in 2026/27.
